[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572828":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":20,"studyPopulation":20,"armGroups":41,"interventions":52,"overallOfficials":20,"centralContacts":61,"locations":67,"responsibleParty":84,"collaborators":20,"id":88,"slug":20,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":20,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":20,"overallStatus":108,"whyStopped":20,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Oedema","Presence of absence will be recorded (1 or 0).","1, 3, 7 an 14 days",[14,18,22,24,27],{"measure":15,"description":16,"timeFrame":17},"Early Healing Score","The score comprises three parameters (Clinical signs of re-epithelialization, hemostasis and inflammation) and ranges from 0 (worst healing) to 10 (best healing)","24 hours post surgery, 3, 7 and 45 days post surgery",{"measure":19,"description":20,"timeFrame":21},"Plaque Index modified by Turesky",null,"1,3,7 and 14 days post surgery",{"measure":23,"description":20,"timeFrame":21},"Gingival Index modified by Trombelli",{"measure":25,"description":26,"timeFrame":21},"Lobene Index modified","Presence of stains or discolorations of teeth and mucosae",{"measure":28,"description":29,"timeFrame":21},"Adverse effects","Disgeusia, mouth ulcers",{"allocation":31,"interventionModel":32,"interventionModelDescription":20,"primaryPurpose":33,"observationalModel":20,"timePerspective":20,"maskingInfo":34},"RANDOMIZED","PARALLEL","SUPPORTIVE_CARE",{"masking":35,"maskingDescription":20,"whoMasked":36},"QUADRUPLE",[37,38,39,40],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[42,47],{"label":43,"type":44,"description":20,"interventionNames":45},"Test group","EXPERIMENTAL",[46],"Other: CHX 0.09% + Citrox + HA",{"label":48,"type":49,"description":20,"interventionNames":50},"Control group","ACTIVE_COMPARATOR",[51],"Drug: CHX 0.12%",[53,57],{"type":6,"name":54,"description":55,"armGroupLabels":56,"otherNames":20},"CHX 0.09% + Citrox + HA","The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.",[43],{"type":58,"name":59,"description":55,"armGroupLabels":60,"otherNames":20},"DRUG","CHX 0.12%",[48],[62],{"name":63,"role":64,"phone":65,"phoneExt":20,"email":66},"Andrea Pilloni, Professor","CONTACT","+39-0649-918152","andrea.pilloni@uniroma1.it",[68],{"facility":69,"status":20,"city":70,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Sapienza University of Rome","Rome","00161","Italy","IT",{"type":75,"coordinates":76},"Point",[77,78],12.51133,41.89193,{"lat":78,"lon":77},[81,83],{"name":82,"role":64,"phone":20,"phoneExt":20,"email":66},"Andrea Pilloni",{"name":20,"role":64,"phone":65,"phoneExt":20,"email":20},{"type":85,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Andrea Pilloni MD DDS MS","Professor","100572828",false,"NCT06738342","Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara","Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara in Patients Undergoing Periodontal Surgery: a Triple-blind, Parallel-arm, Randomized Controlled Trial","CUR_01","Inclusion Criteria:\n\n* More than 20 natural teeth excluding the third molars\n* Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)\n* Have a full mouth plaque score (FMPS) \\\u003C15% before surgery;\n* Have a full mouth bleeding score (FMBS) \\\u003C15% before surgery;\n* Ability and willingness to give written informed consent;\n* Written agreement to participate in the trial.\n\nExclusion Criteria:\n\n* Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation\n* Pregnancy or breastfeeding;\n* Use of medication affecting the healing process;\n* Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;\n* Conditions of the teeth or of the site that contraindicate the surgery (severe mobility, fractures, untreated endodontic lesions, incongruous restorations);\n* Patients with previous periodontal treatment or who were undergoing a course of dental or orthodontic treatment will be also excluded.\n* Tobacco use (10 or more cigarettes per day)\n* Inability to comply with protocol\n* Uncooperative patient",true,"ALL","18 Years","65 Years",{"count":100,"type":101},32,"ESTIMATED","INTERVENTIONAL",[104],"NA","The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.",[107],"Wound Healing","NOT_YET_RECRUITING","2024-12-17",{"date":111,"type":112},"2024-12-20","ACTUAL",{"date":114,"type":101},"2024-12",{"date":116,"type":101},"2025-04",{"name":5,"class":6},1]